MNG219
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.244
- WNT_BETA_CATENIN_SIGNALING+0.210
- PROTEIN_SECRETION+0.196
- UNFOLDED_PROTEIN_RESPONSE+0.182
- HYPOXIA+0.175
- GLYCOLYSIS+0.133
- PI3K_AKT_MTOR_SIGNALING+0.086
- MITOTIC_SPINDLE+0.065
- MYC_TARGETS_V1+0.062
- XENOBIOTIC_METABOLISM+0.062
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.387
- INFLAMMATORY_RESPONSE-0.375
- INTERFERON_GAMMA_RESPONSE-0.355
- TNFA_SIGNALING_VIA_NFKB-0.341
- PANCREAS_BETA_CELLS-0.292
- E2F_TARGETS-0.277
- INTERFERON_ALPHA_RESPONSE-0.271
- IL6_JAK_STAT3_SIGNALING-0.255
- COMPLEMENT-0.218
- G2M_CHECKPOINT-0.208
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1260 | — | — | 0.915 |
| 2 | MNG460 | — | — | 0.845 |
| 3 | MNG848 | — | — | 0.824 |
| 4 | SRR650200 | — | — | 0.787 |
| 5 | MDT-AP-0602 | Med | Medulloblastoma | 0.783 |
| 6 | 9f9dec84-0c2c-4f85-8024-b8fb1de1eb81 | — | — | 0.781 |
| 7 | SRR815232 | GTEX | — | 0.779 |
| 8 | MDT-AP-1357 | Med | Medulloblastoma | 0.758 |
| 9 | MDT-AP-1207 | Med | Medulloblastoma | 0.755 |
| 10 | 28541e4e-2e2b-4772-9566-acf35b31a581 | — | — | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.244 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.196 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.182 | Idelalisib | — uncovered |
| HYPOXIA | 0.175 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.133 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.086 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.065 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.062 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.062 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.054 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.037 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.019 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.015 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.012 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.012 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.004 | Remibrutinib | — uncovered |